TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN
Keywords: ارلوتینیب; TGF-β1; Erlotinib; TKI resistance; NSCLC
مقالات ISI ارلوتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Keywords: ارلوتینیب; Erlotinib; Non-small-cell lung cancer; Chemotherapy; Cancer registry;
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
Keywords: ارلوتینیب; Non-small-cell lung cancer; Sorafenib; Erlotinib
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
Keywords: ارلوتینیب; Erlotinib; NSCLC; Smoking; Increased dose; Pharmacokinetics;
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
Keywords: ارلوتینیب; EGFR; epidermal growth factor receptor; TKIs; tyrosine-kinase inhibitors; NSCLC; non-small-cell lung cancer; PFS; progression-free survival; FISH; fluorescence in-situ hybridization; IHC; immunohistochemistry; ERCC1; excision repair cross-complementation
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial
Keywords: ارلوتینیب; doxycycline; erlotinib; folliculitis; non-small-cell lung cancer; rash; AE; adverse event; CI; confidence interval; CONSORT; CONsolidated Standards Of Reporting Trials; CTCAE; Common Terminology Criteria for Adverse Events; CYTAR; CYcline and TARceva; DI;
Liquid chromatographyâ¿¿tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the Oâ¿¿desmethyl metabolites of erlotinib and gefitinib in human plasma
Keywords: ارلوتینیب; EGFR; epidermal growth factor receptor; IS; internal standard; LCâ¿¿MS/MS; liquid chromatographyâ¿¿tandem mass spectrometry; LLOQ; lower limit of quantification; SRM; selected reaction monitoring; QC; quality control; Afatinib; Erlotinib; Gefitinib; Encor
Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines
Keywords: ارلوتینیب; Pyruvate dehydrogenase kinase; Dichloroacetate; Epidermal growth factor Receptor; Erlotinib; Gefitinib; Drug combination
Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability
Keywords: ارلوتینیب; Erlotinib; Tyrosine kinase inhibitor; Nanosponge; Solubility enhancement; In vitro cytotoxicity; Oral bioavailabilityErlotinib hydrochloride (PubChem CID: 176871); β-Cyclodextrin (PubChem CID: 444041); Ammonium acetate (PubChem CID: 517165); Atorvastatin
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Keywords: ارلوتینیب; NSCLC; Erlotinib; EGFR mutations; Uncommon; Rare;
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
Keywords: ارلوتینیب; Met; Resistance; EGFR; Bim; Erlotinib; AZD9291;
Keratoacanthoma (KA): An update and review
Keywords: ارلوتینیب; BRAF inhibitor; erlotinib; Ferguson-Smith; Grzybowski; histopathology; keratoacanthoma; multiple keratoacanthoma; multiple self-healing squamous epithelioma; squamous cell carcinoma; treatment; GEKA; generalized eruptive keratoacanthoma; KA; keratoacantho
Extended structure–activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties
Keywords: ارلوتینیب; EGFR; Structure–activity relationship (SAR); Thieno[2,3-d]pyrimidine; ADME; Erlotinib; Gefitinib; Zebrafish
EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect
Keywords: ارلوتینیب; ALK rearrangements; Crizotinib; EGFR mutations; Erlotinib; KRAS mutations;
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study
Keywords: ارلوتینیب; Squamous non-small cell lung cancer; Stage IIIB/IV; Erlotinib; Observational; Progression-free survival;
Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies
Keywords: ارلوتینیب; Erlotinib; Tamoxifen; SPE; UPLC-MS/MS; Pharmacokinetics; Rat plasma;
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review
Keywords: ارلوتینیب; Adenocarcinoma; Afatinib; Erlotinib; Exon 19; Gefitinib; L858R; Osimertinib; TKI; T790M;
Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy
Keywords: ارلوتینیب; pH-sensitive; Charge conversion; MSN; Erlotinib; DOX; Synergistic therapy;
Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors
Keywords: ارلوتینیب; Furopyrimidine; EGFR; Erlotinib; Kinase; Chiral drug;
Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors
Keywords: ارلوتینیب; EGFR; Pyrrolopyrimidine; SAR; ADME; Metabolism; Erlotinib;
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors
Keywords: ارلوتینیب; Mutation; Small cell lung cancer; Large cell neuroendocrine carcinoma; EGFR; Never-smoker; Erlotinib; Progression; Resistance;
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer
Keywords: ارلوتینیب; EGFR mutation-negative; Non-squamous non-small-cell lung cancer; Erlotinib; Pemetrexed; Docetaxel; Performance status; Second-line treatment;
Traitement systémique des métastases cérébrales de cancer bronchique
Keywords: ارلوتینیب; Chimiothérapie; Cisplatine; Erlotinib; Géfitinib; Afatinib; Crizotinib; Céritinib; Radiothérapie pancérébraleChemotherapy; Cisplatin; Erlotinib; Gefitinib; Afatinib; Crizotinib; Ceritinib; Whole brain radiotherapy
Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors
Keywords: ارلوتینیب; Chromosome 7 high polysomy; Epidermal growth factors tyrosine wild-type; Erlotinib;
Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice
Keywords: ارلوتینیب; Chronopharmacology; Erlotinib; Circadian rhythms; NSCLC; HCC827;
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer
Keywords: ارلوتینیب; Erlotinib; Non-small-cell lung cancer; Biomarkers; Protein tyrosine phosphatase; PTPRF;
Original StudyIntercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. AÂ Randomized Phase II Clinical Trial
Keywords: ارلوتینیب; Adverse effects; Antineoplastic Combined Chemotherapy; Carcinoma; Docetaxel; Erlotinib;
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911
Keywords: ارلوتینیب; Low-dose; Erlotinib; Non-small cell lung cancer; EGFR mutation;
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Keywords: ارلوتینیب; Biomarker; Patritumab; Erlotinib; Non-small cell lung cancer; HER3; Heregulin
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Keywords: ارلوتینیب; Bevacizumab; Chemotherapy; Erlotinib; Lung cancer; Pemetrexed
Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model
Keywords: ارلوتینیب; Epidermal growth factor receptor tyrosine kinase inhibitor; Erlotinib; Nicotine; Nicotine acetylcholine receptor; Non-small cell lung cancer; Resistance;
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
Keywords: ارلوتینیب; Non-small cell lung cancer; Erlotinib; Proteomic test; Economics; Cost-effectiveness; Chemotherapy;
EGFR and NF-κB: partners in cancer
Keywords: ارلوتینیب; EGFR; gefitinib; erlotinib; NF-κB; resistance; tumor-initiating cells
Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation
Keywords: ارلوتینیب; Erlotinib; Tyrosine kinase inhibitor; Pancreatic cancer; Cyclodextrin; Sulfobutyl ether β-cyclodextrin; Solubility enhancement; Erlotinib hydrocholide (PubChem CID: 176871); α-Cyclodextrin (PubChem CID: 444913); β-Cyclodextrin (PubChem CID: 444041); γ
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Keywords: ارلوتینیب; HER; human epidermal growth factor receptor; NSCLC; non-small cell lung cancer; DLT; dose-limiting toxicity; MTD; maximum tolerated dose; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; RECIST; response evaluation criteria in solid t
Quel traitement de première ligne en cas de mutation activatrice de l'EGFR dans les cancers bronchiques non à petites cellules (CBNPC) disséminés ?
Keywords: ارلوتینیب; Mutation activatrice de l'EGF-R; CBNPC non épidermoïde; Addiction oncogénique; Résistance secondaire; Traitement de première ligne; TKI de l'EGF-R; Afatinib; Erlotinib; Gefitinib; Activating mutation of EGF-R; Non-squamous cell NSCLC; Oncogenic a
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib
Keywords: ارلوتینیب; Brain metastases; EGFR mutation; Lung adenocarcinoma; Gefitinib; Erlotinib
Sécurité de la réintroduction de l'erlotinib à faible posologie après un syndrome main-pied induit par l'erlotinib dans une tumeur de Pancoast-Tobias
Keywords: ارلوتینیب; Syndrome main-pied; Erlotinib; Inhibiteurs de l'EGFR; Inhibiteurs du VEGF; Toxidermies; Hand-foot syndrome; Erlotinib; EGFR inhibitors; VEGF inhibitors; Cutaneous side-effects;
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Keywords: ارلوتینیب; CDK inhibitor; Dinaciclib; NSCLC; Phase 2; Erlotinib; Monotherapy;
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer
Keywords: ارلوتینیب; Erlotinib; Chemotherapy; Elderly; NSCLC;
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE)
Keywords: ارلوتینیب; Non-small cell lung cancer; Lung adenocarcinoma; KRAS; EGFR; Mutation status; Erlotinib;
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
Keywords: ارلوتینیب; Myelodysplastic syndrome; Higher risk; Erlotinib;
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines
Keywords: ارلوتینیب; SOX2; Non-small cell lung cancer; EGFR; Akt; Erlotinib; H1975; HCC827
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903)
Keywords: ارلوتینیب; EGFR-TKI; Wild type EGFR; Re-evaluation; Erlotinib; HGF;
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer
Keywords: ارلوتینیب; Non-small-cell lung cancer; Geriatric; Erlotinib; Epidermal growth factor receptor; Tyrosine-kinase inhibitor; Interstitial lung disease;
Traitement par erlotinib après une toxicité hépatique induite par le géfitinib : revue de la littérature à propos d'une observation
Keywords: ارلوتینیب; cancer bronchique non à petites cellules; géfitinib; erlotinib; inhibiteur de l'activité tyrosine kinase de l'EGFR; hépatotoxicité; non-small-cell lung carcinoma; gefinitib; erlotinib; molecular inhibitors of EGFR tyrosine kinase activity; hepato
Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis
Keywords: ارلوتینیب; Afatinib; Diarrhea; Erlotinib; Gefitinib; Skin rash
Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis
Keywords: ارلوتینیب; Erlotinib; Gefitinib; Human β-defensins
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
Keywords: ارلوتینیب; Non–small-cell lung cancer; Gefitinib; Erlotinib; Epidermal growth factor receptor mutation
Adsorption and desorption of tyrosine kinase inhibitor erlotinib on gold nanoparticles
Keywords: ارلوتینیب; Raman spectroscopy; Erlotinib; Gold nanoparticles; Interfacial structures; Density functional theory